A regulatory pathway needs to be developed if the UK is to reap the benefits of bacteriophage therapy, Applied Microbiology International (AMI) has warned.
Our submission to the UK Parliament highlights the scientific case, regulatory gaps, and UK opportunities for harnessing bacteriophages to tackle antimicrobial resistance.
